Neurotrope, Inc. Common
NTRP
NTRP was delisted on the 1st of December, 2020.
21 hedge funds and large institutions have $811K invested in Neurotrope, Inc. Common in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 9 reducing their positions, and 13 closing their positions.
32% more call options, than puts
Call options by funds: $70K | Put options by funds: $53K
22% less capital invested
Capital invested by funds: $1.04M → $811K (-$228K)
28% less funds holding
Funds holding: 29 → 21 (-8)
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
89% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$21.6K |
| 2 |
HF
HRT Financial
New York
|
+$8.31K |
| 3 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$4.83K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$544 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCMI
Oaktop Capital Management II
Chatham,
New Jersey
|
-$95K |
| 2 |
VF
Virtu Financial
New York
|
-$52K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$51K |
| 4 |
CC
Cannell & Co
New York
|
-$48.9K |
| 5 |
Renaissance Technologies
New York
|
-$34K |
NTRP Hedge Fund Activity: Q4 2019 in Review
21 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Neurotrope, Inc. Common (NTRP) for Q4 2019, worth a combined $811K — down 22% from $1.04M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of NTRP and 5 opened new positions — a net loss of 8 holders — while 9 trimmed existing stakes and 1 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $21.6K. The largest seller was Oaktop Capital Management II, exiting entirely with an estimated $95K sold.
- 21 institutional investors held Neurotrope, Inc. Common (NTRP) as of Q4 2019, down from 29 in Q3 2019.
- Funds reported $811K of Neurotrope, Inc. Common stock for Q4 2019, down 22% quarter-over-quarter.
- 5 funds opened new Neurotrope, Inc. Common positions in Q4 2019 and 13 closed out, a net change of -8 holders.
- The largest Neurotrope, Inc. Common buyer in Q4 2019 was Susquehanna International Group, an estimated $21.6K added.
- The largest Neurotrope, Inc. Common seller in Q4 2019 was Oaktop Capital Management II, an estimated $95K sold.
Based on aggregated 13F filings for Q4 2019.